

## Special Issue

# Antimicrobial Stewardship in Critical Care

### Message from the Guest Editors

The aftermath of the COVID-19 pandemic highlighted the importance antimicrobial stewardship in critically ill patients, as these patients are often most likely to receive broad-spectrum antimicrobial therapy. During the pandemic, stewardship was often not a focal point for hospitalized patients; however, many institutions are now reprioritizing antimicrobial stewardship efforts, including in critically ill patients. This Special Issue aims to capture impactful manuscripts in content areas including but not limited to:

- Examining the intersection of COVID-19 and antimicrobial stewardship;
- Lessons learned from the pandemic as it pertains to stewardship;
- Novel antimicrobial stewardship approaches in the critically ill patient population;
- Stewardship strategies with new antimicrobial therapies;
- De-escalation strategies in the ICU.

---

### Guest Editors

Dr. David Cluck  
Dr. Jennifer Tharp  
Dr. Leslie Hamilton

---

### Deadline for manuscript submissions

closed (31 December 2023)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/128102](https://mdpi.com/si/128102)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)